Details for New Drug Application (NDA): 020173
✉ Email this page to a colleague
NDA 020173 describes TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, which is a drug marketed by Baxter Hlthcare and is included in one NDA. Additional details are available on the TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER profile page.
The generic ingredient in TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER is amino acids; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride. There are three hundred and fifty drug master file entries for this compound. Additional details are available on the amino acids; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride profile page.
The generic ingredient in TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER is amino acids; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride. There are three hundred and fifty drug master file entries for this compound. Additional details are available on the amino acids; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride profile page.
Summary for 020173
| Tradename: | TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER |
| Applicant: | Baxter Hlthcare |
| Ingredient: | amino acids; magnesium chloride; potassium phosphate, dibasic; sodium acetate; sodium chloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML | ||||
| Approval Date: | Oct 27, 1995 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML | ||||
| Approval Date: | Oct 27, 1995 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
